The present invention relates to a pharmaceutical composition comprising at least one peptide consisting of a minimum of 8 and a maximum of 50 amino acid residues comprising amino acid residues 1 to 8 of a rhinovirus capsid protein selected from the group consisting of VP1, VP2, VP3 and VP4.

Vaccine compositions comprising a plurality of immunogens attached to a carrier for inducing an immune response against a pathogen selected from the Anaplasma, Babesia, Borrelia, and Chlamydia genera. Vaccine compositions comprising multivalent carriers and related methods using the vaccine compositions in various therapeutic and prophylactic applications for inducing an immune response against, treating, or preventing an infection caused by the Anaplasma, Babesia, Borrelia, or Chlamydia pathogens, and the related diseases thereof.

The present invention provides a method for identifying the amino acid sequence of a naturally occurring polyprotein from a group A or C rhinovirus that can be used as an immunogen capable of eliciting an immune response against rhinoviruses from multiple serotypes within the same group. The invention also provides immunogenic compositions that comprise at least one mRNA comprising a non-naturally occurring optimized nucleic acid encoding a polyprotein identified by this method.